Condition: Coronary Artery Disease · Ischemic Heart Disease · Sponsor: Fundación EPIC
The study is designed as a prospective, multi-center, observational PMCF (post-market clinical follow-up) study of the Ultimaster Nagomi™ \_stent (lengths of 38, 44 and 50 mm) in the treatment of coronary artery disease according to the indications approved in the CE marking.
This description comes directly from the study's public registry record.
TAMARA GARCIA CAMARERO, MD, PhD · 0034615420460 · tgcamarero@gmail.com
FUNDACION EPIC · 00987876135 · iepic@fundacionepic.org
Always discuss trial participation with your own doctor first.
| Hospital Universitario de Cabueñes | Cabueñes, Spain | Recruiting |
| Hospital General Universitario de Elche | Elche, Spain | Recruiting |
| Hospital Universitario Juan Ramón Jiménez | Huelva, Spain | Recruiting |
| Hospital Universitario de Leon | León, Spain | Recruiting |
| Hospital Universitario Regional de Málaga | Málaga, Spain | Recruiting |
| Hospital Universitario de Navarra | Pamplona, Spain | Recruiting |
| Hospital Universitario Marqués de Valdecilla | Santander, Spain | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07399002